Safety and immunogenicity of heterologous prime/boost inactivated COVID-19 vaccine and viral vector vaccine: an experimental clinical study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210628005

Enrollment

100

Registered

2021-06-28

Start date

2021-06-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunogenicity COVID-19, SARS-CoV-2, Priming effect, Boost, Vaccine, Clinical trial, Antibody, Immunity, Interchangeability

Interventions

This group recieved coronavac vaccine as the first dose and ChAdOx0-1 vaccine as the second dose.,This group recieved ChAdOx0-1 vaccine as the first dose and coronavac vaccine as the second dose.

Experimental Drug,Experimental Drug

Coronavac,Astrazeneka

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Healthy individuals above 18 years of age 2. Have never been infected with SARS-CoV-2 3. Have never been vaccinated with COVID-19 vaccine 4. Not in the immunocompromised status

Exclusion criteria

Exclusion criteria: 1. Are being infected with COVID-19 2. Bleeding disorders

Design outcomes

Primary

Measure	Time frame
immunogenicity 1 month post two doses anti-spike RBD IgG	—

Secondary

Measure	Time frame
safety 7 days after vaccination incidence of adverse events	—

Countries

Thailand

Contacts

Public ContactNasamon Wanlapakorn

Chulalongkorn University

nasamon.w@chula.ac.th022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026